amylin glp 1 Amycretin — a novel obesity treatment that targets both GLP-1 and receptors — has shown early success in phase testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD Amylin Revisited: A 5-Year Perspective

With the needle in the liquid, pull the plunger beyond your designated dose

Across the SURPASS program, tirzepatide reduced SBP vs

These side effects are as follows: Articular sensitivity Peripheral paresthesia Hyperphagic response Cephalic discomfort Gastrointestinal disturbance Localized dermal reaction at administration site Affective variability Note: Reported side effects in preclinical studies were generally mild and manageable under controlled laboratory conditions

Diabetologia.1986 Jan;29(1):46-52

Baumgarten, K

TBC1D9B was particularly interesting because of its putative function as a GTPase-activating protein (GAP) and its hypothesized role in endo-lysosomal trafficking, possibly by modulating the function of RAB proteins (i.e., RAB11A) 38 and/or related small GTPases